At a Glance
- Companies: Roche and Nurix Therapeutics
- Upfront payment: $700 million
- Focus area: BTK degradation
- Lead indication: Chronic lymphocytic leukaemia
- Next steps: Advance the programme through development
What happened?
Roche has entered an exclusive licensing and collaboration agreement with Nurix Therapeutics centred on a BTK degrader programme. The deal includes a $700 million upfront payment and gives Roche rights to advance the asset for chronic lymphocytic leukaemia and additional indications.
Why does it matter?
BTK has been a major target in haematology, but resistance and tolerability issues have created room for new approaches. A degrader strategy could offer a different way to suppress the target, potentially broadening treatment options in CLL and related diseases.
Who’s behind it?
Roche is a global pharmaceutical company with a large haematology portfolio, while Nurix specialises in targeted protein degradation. The collaboration gives Roche access to Nurix’s degrader discovery platform and gives Nurix a major validation event for its technology.
How was it achieved?
The agreement is structured as an exclusive licensing and collaboration pact, with Roche making a substantial upfront payment for development rights. That arrangement suggests Roche will take a leading role in later-stage development and commercialisation if the programme succeeds.
What’s next?
The partners will move the BTK degrader programme through further preclinical and clinical development, starting with CLL. If the asset performs well, the collaboration could expand into broader haematology or other immune-related indications.